Dengue igm positive is dangerous

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute or convalescent." This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. Component Interpretation Dengue Fever Virus Antibody, IgG 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgG antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgG antibody to dengue fever virus detected, which may indicate a current or past infection. Dengue Fever Virus Antibody, IgM 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgM antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgM antibody to dengue fever virus detected, which may indicate a current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection. CPT Codes The American Medical Association Current Procedural Terminolo...

Search Cancel • TOPICS • • • • • • • • • • • OPINION • • • • • • • • • PODCASTS • • • • RESOURCES • • • • • • STAT+ • Exclusive analysis of biotech, pharma, and the life sciences • • • Topics • • • • • • Columns • • • • Tools • • • • Events • • Team • • • • Account • • • • • More • • • Follow Us • • • • • • • • • • • • For decades there has been a counterintuitive and hotly debated theory about And now American and Nicaraguan scientists have published evidence that may silence the skeptics. Antibody-dependent enhancement, or ADE as it’s known in scientific circles, can happen, they reported, when subsequent infection occurs at a time when antibodies generated by the prior infection have fallen to a specific low range. Nikos Vasilakis, an associate professor of pathology at the University of Texas Medical Branch, used to be among the disbelievers — primarily because, though ADE was seen in lab experiments (in vitro), proof in people (in vivo) had been absent. “I’m one of those people who for years I was questioning that,” he admitted. Related: Cheap, fast test for Zika and dengue could cost just $1 “This paper, what it does, it shows for the first time the narrow range of antibody concentrations … that actually produces enhancement of disease in vivo,” said Vasilakis, who was not involved in the study. “I have bias against ADE in general, but this is a very good study.” The work was published A theory borne out One might expect that the scientist who came up with the theory...

Dengue virus (DV) is a globally distributed flavivirus with 4 distinct serotypes (DV-1, -2, -3, -4). It is primarily transmitted by the Aedes aegypti mosquito, which is found throughout the tropical and subtropical regions of over 100 countries. DV poses a significant worldwide public health threat with approximately 2.5 to 3 billion people residing in DV endemic areas, among whom 100 to 200 million individuals will be infected, and approximately 30,000 patients will succumb to the disease, annually. Following dengue infection, the incubation period varies from 3 to 7 days, and while some infections remain asymptomatic, the majority of individuals will develop classic dengue fever. Symptomatic patients become acutely febrile and present with severe musculoskeletal pain, headache, retro-orbital pain, and a transient macular rash, most often observed in children. Fever defervescence signals disease resolution in most individuals. However, children and young adults remain at increased risk for progression to dengue hemorrhagic fever and dengue shock syndrome, particularly during repeat infection with a new DV serotype. Detection of dengue-specific IgM and IgG-class antibodies remains the most commonly utilized diagnostic method. Seroconversion occurs approximately 3 to 7 days following exposure, and therefore, testing of acute and convalescent sera may be necessary to make the diagnosis. As an adjunct to serologic testing, identification of early DV infection may be made by d...

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute or convalescent." This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. Component Interpretation Dengue Fever Virus Antibody, IgG 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgG antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgG antibody to dengue fever virus detected, which may indicate a current or past infection. Dengue Fever Virus Antibody, IgM 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgM antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgM antibody to dengue fever virus detected, which may indicate a current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection. CPT Codes The American Medical Association Current Procedural Terminolo...

Search Cancel • TOPICS • • • • • • • • • • • OPINION • • • • • • • • • PODCASTS • • • • RESOURCES • • • • • • STAT+ • Exclusive analysis of biotech, pharma, and the life sciences • • • Topics • • • • • • Columns • • • • Tools • • • • Events • • Team • • • • Account • • • • • More • • • Follow Us • • • • • • • • • • • • For decades there has been a counterintuitive and hotly debated theory about And now American and Nicaraguan scientists have published evidence that may silence the skeptics. Antibody-dependent enhancement, or ADE as it’s known in scientific circles, can happen, they reported, when subsequent infection occurs at a time when antibodies generated by the prior infection have fallen to a specific low range. Nikos Vasilakis, an associate professor of pathology at the University of Texas Medical Branch, used to be among the disbelievers — primarily because, though ADE was seen in lab experiments (in vitro), proof in people (in vivo) had been absent. “I’m one of those people who for years I was questioning that,” he admitted. Related: Cheap, fast test for Zika and dengue could cost just $1 “This paper, what it does, it shows for the first time the narrow range of antibody concentrations … that actually produces enhancement of disease in vivo,” said Vasilakis, who was not involved in the study. “I have bias against ADE in general, but this is a very good study.” The work was published A theory borne out One might expect that the scientist who came up with the theory...

Dengue virus (DV) is a globally distributed flavivirus with 4 distinct serotypes (DV-1, -2, -3, -4). It is primarily transmitted by the Aedes aegypti mosquito, which is found throughout the tropical and subtropical regions of over 100 countries. DV poses a significant worldwide public health threat with approximately 2.5 to 3 billion people residing in DV endemic areas, among whom 100 to 200 million individuals will be infected, and approximately 30,000 patients will succumb to the disease, annually. Following dengue infection, the incubation period varies from 3 to 7 days, and while some infections remain asymptomatic, the majority of individuals will develop classic dengue fever. Symptomatic patients become acutely febrile and present with severe musculoskeletal pain, headache, retro-orbital pain, and a transient macular rash, most often observed in children. Fever defervescence signals disease resolution in most individuals. However, children and young adults remain at increased risk for progression to dengue hemorrhagic fever and dengue shock syndrome, particularly during repeat infection with a new DV serotype. Detection of dengue-specific IgM and IgG-class antibodies remains the most commonly utilized diagnostic method. Seroconversion occurs approximately 3 to 7 days following exposure, and therefore, testing of acute and convalescent sera may be necessary to make the diagnosis. As an adjunct to serologic testing, identification of early DV infection may be made by d...

Dengue virus (DV) is a globally distributed flavivirus with 4 distinct serotypes (DV-1, -2, -3, -4). It is primarily transmitted by the Aedes aegypti mosquito, which is found throughout the tropical and subtropical regions of over 100 countries. DV poses a significant worldwide public health threat with approximately 2.5 to 3 billion people residing in DV endemic areas, among whom 100 to 200 million individuals will be infected, and approximately 30,000 patients will succumb to the disease, annually. Following dengue infection, the incubation period varies from 3 to 7 days, and while some infections remain asymptomatic, the majority of individuals will develop classic dengue fever. Symptomatic patients become acutely febrile and present with severe musculoskeletal pain, headache, retro-orbital pain, and a transient macular rash, most often observed in children. Fever defervescence signals disease resolution in most individuals. However, children and young adults remain at increased risk for progression to dengue hemorrhagic fever and dengue shock syndrome, particularly during repeat infection with a new DV serotype. Detection of dengue-specific IgM and IgG-class antibodies remains the most commonly utilized diagnostic method. Seroconversion occurs approximately 3 to 7 days following exposure, and therefore, testing of acute and convalescent sera may be necessary to make the diagnosis. As an adjunct to serologic testing, identification of early DV infection may be made by d...

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute or convalescent." This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. Component Interpretation Dengue Fever Virus Antibody, IgG 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgG antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgG antibody to dengue fever virus detected, which may indicate a current or past infection. Dengue Fever Virus Antibody, IgM 1.64 IV or less: Negative - No significant level of detectable dengue fever virus IgM antibody. 1.65-2.84 IV: Equivocal - Questionable presence of antibodies. Repeat testing in 10-14 days may be helpful. 2.85 IV or greater: Positive - IgM antibody to dengue fever virus detected, which may indicate a current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection. CPT Codes The American Medical Association Current Procedural Terminolo...

Search Cancel • TOPICS • • • • • • • • • • • OPINION • • • • • • • • • PODCASTS • • • • RESOURCES • • • • • • STAT+ • Exclusive analysis of biotech, pharma, and the life sciences • • • Topics • • • • • • Columns • • • • Tools • • • • Events • • Team • • • • Account • • • • • More • • • Follow Us • • • • • • • • • • • • For decades there has been a counterintuitive and hotly debated theory about And now American and Nicaraguan scientists have published evidence that may silence the skeptics. Antibody-dependent enhancement, or ADE as it’s known in scientific circles, can happen, they reported, when subsequent infection occurs at a time when antibodies generated by the prior infection have fallen to a specific low range. Nikos Vasilakis, an associate professor of pathology at the University of Texas Medical Branch, used to be among the disbelievers — primarily because, though ADE was seen in lab experiments (in vitro), proof in people (in vivo) had been absent. “I’m one of those people who for years I was questioning that,” he admitted. Related: Cheap, fast test for Zika and dengue could cost just $1 “This paper, what it does, it shows for the first time the narrow range of antibody concentrations … that actually produces enhancement of disease in vivo,” said Vasilakis, who was not involved in the study. “I have bias against ADE in general, but this is a very good study.” The work was published A theory borne out One might expect that the scientist who came up with the theory...

Search Cancel • TOPICS • • • • • • • • • • • OPINION • • • • • • • • • PODCASTS • • • • RESOURCES • • • • • • STAT+ • Exclusive analysis of biotech, pharma, and the life sciences • • • Topics • • • • • • Columns • • • • Tools • • • • Events • • Team • • • • Account • • • • • More • • • Follow Us • • • • • • • • • • • • For decades there has been a counterintuitive and hotly debated theory about And now American and Nicaraguan scientists have published evidence that may silence the skeptics. Antibody-dependent enhancement, or ADE as it’s known in scientific circles, can happen, they reported, when subsequent infection occurs at a time when antibodies generated by the prior infection have fallen to a specific low range. Nikos Vasilakis, an associate professor of pathology at the University of Texas Medical Branch, used to be among the disbelievers — primarily because, though ADE was seen in lab experiments (in vitro), proof in people (in vivo) had been absent. “I’m one of those people who for years I was questioning that,” he admitted. Related: Cheap, fast test for Zika and dengue could cost just $1 “This paper, what it does, it shows for the first time the narrow range of antibody concentrations … that actually produces enhancement of disease in vivo,” said Vasilakis, who was not involved in the study. “I have bias against ADE in general, but this is a very good study.” The work was published A theory borne out One might expect that the scientist who came up with the theory...